Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1999 Oct;81(4):667–671. doi: 10.1038/sj.bjc.6690745

Chromogranin A, a significant prognostic factor in small cell lung cancer

L Drivsholm 1, L I Paloheimo 2, K Østerlind 3
PMCID: PMC2362890  PMID: 10574253

Abstract

Chromogranin A (CgA) is a protein present in neuroendocrine vesicles. Small cell lung cancer (SCLC) is considered a neuroendocrine tumour. It is possible to demonstrate CgA expression in SCLC by immunohistochemical methods. Since CgA is released to the circulation it might also work as a clinical tumour marker. We used a newly developed two-site enzyme-linked immunosorbent assay for CgA in plasma from 150 newly diagnosed patients with SCLC. Follow-up was for a minimum of 5 years. Thirty-seven per cent of the patients had elevated pretreatment values and the values were significantly related to stage of disease. Multivariable analysis by Cox's proportional hazard model including nine known prognostic factors disclosed performance status as the most influential prognostic factor followed by stage of disease, CgA and LDH. A simple prognostic index (PI) could be established based on these four pretreatment features. In this way the patients could be separated into three groups with significant different prognosis. The median survival and 95% confidence intervals for the three groups were as follows: 424 days (311–537), 360 days (261–459) and 174 days (105–243). © 1999 Cancer Research Campaign

Keywords: chromogranin A, small cell lung cancer, tumour marker, prognostic factors

Full Text

The Full Text of this article is available as a PDF (65.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Blaschko H., Comline R. S., Schneider F. H., Silver M., Smith A. D. Secretion of a chromaffin granule protein, chromogranin, from the adrenal gland after splanchnic stimulation. Nature. 1967 Jul 1;215(5096):58–59. doi: 10.1038/215058a0. [DOI] [PubMed] [Google Scholar]
  2. Buccheri G., Ferrigno D. Prognostic factors in lung cancer: tables and comments. Eur Respir J. 1994 Jul;7(7):1350–1364. doi: 10.1183/09031936.94.07071350. [DOI] [PubMed] [Google Scholar]
  3. Ferrigno D., Buccheri G. Clinical applications of serum markers for lung cancer. Respir Med. 1995 Oct;89(9):587–597. doi: 10.1016/0954-6111(95)90225-2. [DOI] [PubMed] [Google Scholar]
  4. Helle K. B., Angeletti R. H. Chromogranin A: a multipurpose prohormone? Acta Physiol Scand. 1994 Sep;152(1):1–10. doi: 10.1111/j.1748-1716.1994.tb09779.x. [DOI] [PubMed] [Google Scholar]
  5. Hendy G. N., Bevan S., Mattei M. G., Mouland A. J. Chromogranin A. Clin Invest Med. 1995 Feb;18(1):47–65. [PubMed] [Google Scholar]
  6. Hirsch F. R., Dombernowsky P., Hansen H. H. Treatment of small cell lung cancer: the Copenhagen experience. Anticancer Res. 1994 Jan-Feb;14(1B):317–319. [PubMed] [Google Scholar]
  7. Hsiao R. J., Mezger M. S., O'Connor D. T. Chromogranin A in uremia: progressive retention of immunoreactive fragments. Kidney Int. 1990 Mar;37(3):955–964. doi: 10.1038/ki.1990.71. [DOI] [PubMed] [Google Scholar]
  8. Hsiao R. J., Parmer R. J., Takiyyuddin M. A., O'Connor D. T. Chromogranin A storage and secretion: sensitivity and specificity for the diagnosis of pheochromocytoma. Medicine (Baltimore) 1991 Jan;70(1):33–45. [PubMed] [Google Scholar]
  9. Iacangelo A. L., Eiden L. E. Chromogranin A: current status as a precursor for bioactive peptides and a granulogenic/sorting factor in the regulated secretory pathway. Regul Pept. 1995 Aug 22;58(3):65–88. doi: 10.1016/0167-0115(95)00069-n. [DOI] [PubMed] [Google Scholar]
  10. Johnson P. W., Joel S. P., Love S., Butcher M., Pandian M. R., Squires L., Wrigley P. F., Slevin M. L. Tumour markers for prediction of survival and monitoring of remission in small cell lung cancer. Br J Cancer. 1993 Apr;67(4):760–766. doi: 10.1038/bjc.1993.138. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Konecki D. S., Benedum U. M., Gerdes H. H., Huttner W. B. The primary structure of human chromogranin A and pancreastatin. J Biol Chem. 1987 Dec 15;262(35):17026–17030. [PubMed] [Google Scholar]
  12. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966 Mar;50(3):163–170. [PubMed] [Google Scholar]
  13. Murray S. S., Deaven L. L., Burton D. W., O'Connor D. I., Mellon P. L., Deftos L. J. The gene for human chromogranin A (CgA) is located on chromosome 14. Biochem Biophys Res Commun. 1987 Jan 15;142(1):141–146. doi: 10.1016/0006-291x(87)90462-1. [DOI] [PubMed] [Google Scholar]
  14. O'Connor D. T., Deftos L. J. How sensitive and specific is measurement of plasma chromogranin A for the diagnosis of neuroendocrine neoplasia? Ann N Y Acad Sci. 1987;493:379–386. doi: 10.1111/j.1749-6632.1987.tb27219.x. [DOI] [PubMed] [Google Scholar]
  15. Osterlind K., Andersen P. K. Prognostic factors in small cell lung cancer: multivariate model based on 778 patients treated with chemotherapy with or without irradiation. Cancer Res. 1986 Aug;46(8):4189–4194. [PubMed] [Google Scholar]
  16. Rosa P., Gerdes H. H. The granin protein family: markers for neuroendocrine cells and tools for the diagnosis of neuroendocrine tumors. J Endocrinol Invest. 1994 Mar;17(3):207–225. doi: 10.1007/BF03347721. [DOI] [PubMed] [Google Scholar]
  17. Sobol R. E., O'Connor D. T., Addison J., Suchocki K., Royston I., Deftos L. J. Elevated serum chromogranin A concentrations in small-cell lung carcinoma. Ann Intern Med. 1986 Nov;105(5):698–700. doi: 10.7326/0003-4819-105-5-698. [DOI] [PubMed] [Google Scholar]
  18. Takiyyuddin M. A., Cervenka J. H., Pandian M. R., Stuenkel C. A., Neumann H. P., O'Connor D. T. Neuroendocrine sources of chromogranin-A in normal man: clues from selective stimulation of endocrine glands. J Clin Endocrinol Metab. 1990 Aug;71(2):360–369. doi: 10.1210/jcem-71-2-360. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES